Comparative evaluation of hematological parameters and instrument performance in single and double plateletpheresis procedures using Haemonetics MCS+ and Trima Accel systems - 26/11/24

Doi : 10.1016/j.tracli.2024.11.002

Niloufar Kazemi Babaahmadi ^a, Maryam Kheirandish ^a,^⁎ , Amir Teimourpour ^b, Saeed Mohammadi ^c,^d, Amir Masoud Nazemi ^b
^a Department of Immunology, Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran
^b Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran
^c Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
^d Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran

^⁎Corresponding author at: Maryam Kheirandish. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Iranian Blood Transfusion Organization (IBTO), Tehran, Iran.Maryam Kheirandish. Blood Transfusion Research CenterHigh Institute for Research and Education in Transfusion MedicineIranian Blood Transfusion Organization (IBTO)TehranIran

Sous presse. Épreuves corrigées par l'auteur. Disponible en ligne depuis le Tuesday 26 November 2024

Highlights

•	Due to high demand and shortage, double-dose platelet is produced as long as no harm is inflicted on the donors.
•	Donors’ hematological parameters stay within the normal range after double-dose platelet donation.
•	The Trima Accel device may offer superior efficiency and processing times compared to the Haemonetics MCS+.

Le texte complet de cet article est disponible en PDF.

Abstract

Objectives

Plateletpheresis (PP) has become increasingly prevalent due to its cost-effectiveness and fewer immunological and infectious complications for recipients. This study compares hematological indices of platelet donors and instrument-related parameters in high-yield PP donors using Haemonetics MCS+ and Trima Accel.

Methods

Eligible and healthy PP donors meeting the platelet donation criteria were randomly selected.19 single-dose platelet (SDP), and 26 double-dose platelet (DDP) donors underwent PP using the Haemonetics MCS+, while 21 SDP and 21 DDP donors were processed using the Trima Accel system. Complete Blood Count (CBC) and hematological indices of donors between groups with both devices were measured with the cell counter. Platelet yield, collection efficiency (CE), and collection rate (CR) were evaluated for both devices. Results were reported using R-4.3.2 software and a p-value <0.05 was considered statistically significant.

Results

The Trima Accel processed significantly more blood volume and had shorter procedure times than MCS+. Platelet yield in the SDP group with Trima Accel was significantly higher than the Haemonetics MCS+. The Trima Accel demonstrated a significantly higher CR and CE than the MCS+ in both SDP and DDP groups. Post-PP lymphocyte counts significantly decreased with the Trima compared to the MCS+ in the SDP group. However, post-PP hematocrit (HCT), mean corpuscular volume (MCV), and mean platelet volume (MPV) in the DDP group with the MCS+ were significantly lower than Trima.

Conclusion

Double-dose plateletpheresis (DDP) offers advantages in cost-effectiveness and platelet production, and although it reduces some hematological indices, these remain within normal limits. The Trima Accel may offer superior efficiency and processing times compared to the MCS+. However, careful monitoring of DDP donors following AABB standards remains essential.

Le texte complet de cet article est disponible en PDF.

Keywords : Plateletpheresis, Platelet Transfusions, Blood Donation, Haemonetics MCS+, Trima Accel, Hematological Parameters, Instrument Performance